Business Model Canvas: SLC25A45-Based Metabolic Biomarker Panel
A diagnostic blood test measuring SLC25A45 mutation status and methylated amino acid levels to identify a specific metabolic phenotype that may influence response to GLP-1 receptor agonist weight-loss drugs. The panel targets potential bottlenecks in carnitine biosynthesis that could hinder the body's ability to mobilize fat.
The framework reveals a high-dependency model where value is contingent on bridging the gap between mouse-model evidence and human clinical validation. It positions the venture as a specialized B2B companion diagnostic provider rather than a direct-to-consumer test, shifting the primary risk to clinical correlation studies.
Key Partners3
Key Activities3
Key Resources3
Value Propositions3
Customer Relationships2
Channels3
Customer Segments3
Cost Structure3
Revenue Streams3
Necessary to define how value is captured from pharmaceutical companies and the specific delivery mechanism for clinical trial stratification. · Generated 2026-09-09 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated